Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients

Journal of Hypertension

Volumn 16, Issue 3, 1998, Pages 385-393

  Pechère Bertschi, Antoinette ^a   Nussberger, Jürg ^a   Decosterd, Laurent ^a   Armagnac, Catherine ^a   Sissmann, Joëlle ^a   Bouroudian, Marc ^a   Brunner, Hans R ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II receptor antagonist; Humans; Hypertension; Renal hemodynamics

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; RECEPTOR SUBTYPE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; MALE; PRIORITY JOURNAL; TIME; VASODILATATION;

EID: 0031890860     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816030-00016     Document Type: Article

References (32)

1. Keane WF, Anderson S, Aurell M, DeZeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency: current experience and future directions. Ann Intern Med 1989; 111:503-516.
2. Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42:463-479.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
5. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 206:205-251.
6. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83:1333-1342.
7. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51:513-521.
8. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25:14-19.
9. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345-1350.
10. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, et al. Blood pressure effects of the angiotensin receptor blocker, losartan. Arch Intern Med 1995; 155:405-411.
11. van den Meiracker AH, Admiraal PJJ, Janssen JA, Kroodsma J-M, de Ronde WAM, Boomsma F, et al. Hemodynamic and biochemical effects of the AT, receptor antagonist irbesartan in hypertension. Hypertension 1995; 25:22-29.
12. Burnier M, Brunner HR. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Neph 1996; 4(suppl 1):41-46.
13. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45:861-867.
14. Jover B, Saladini D, Nafrialdi N, Dupont M, Mimran A. Effect of losartan and enalapril on the renal adaptation to sodium restriction in rat. Am J Physiol 1994; 267:F281-F288.
15. Jover B, Hérizi A, Mimran A. Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Hypertension 1996; 27:79-84.
16. Burnier M, Brunner HR, Angiotensin II receptor antagonists and the kidney, Curr Opin Nephrol Hypertens 1994; 3:537-545.
17. McNabb WR, Noormohamed FH, Brooks BA, Till AE, Lant AF. Effects of repeated doses of enalapril and renal function in man. Br J Clin Pharmacol 1985; 19:353-361.
18. Vos PF, Boer P, Koomans HA. Effects of enalapril on renal sodium handling in healthy subjects on low, intermediate, and high sodium intake. J Cardiovasc Pharmacol 1993; 22:27-32.
19. Burnier M, Rutschmann B, Nussberger J, Versaggi S, Shahinfar S, Waeber B, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22:339-347.
20. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25:602-609.
21. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin II receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996; 90:205-213.
22. Estelberger W, Petek W, Zitta S, Mauric A, Horn S, Holzer H, et al. Determination of the glomerular filtration rate by identification of sinistrin kinetics. Eur J Clin Chem Clin Biochem 1995; 33:201-209.
23. Séchaud R, Décosterd LA, Pechère-Bertschi A, Biollaz J, Kesselring UW. Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection. J Pharmaceut Biochem Anal 1996; 14:483-490.
24. Friedman SM, Polley JR, Friedman CL. The clearance of inulin and sodium p-aminohippurate in the rat. Am J Physiol 1947; 150:340-352.
25. Nussberger J, Waeber B, Brunner HR, Burris JF, Vetter W. Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med 1984, 104:789-796.
26. Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987; 9:39-44.
27. Nussberger J, Keller I, Waeber B, Brunner HR. Angiotensin II measurement with high-affinity monoclonal antibodies. J Hypertens 1988; 6 (suppl 4):S424-S425.
28. Meredith PA, Donnelly R, Elliott HL, Howie CA, Reid JL. Prediction of the antihypertensive response to enalapril. J Hypertens 1990; 8:1085-1090.
29. Dupont AG, van der Niepen P, Six RO. Placebo does not lower ambulatory blood pressures. Br J Clin Pharmacol 1987; 24:106-109.
30. O'Brien E, Murphy J, Tyndall A, Atkins N, Mee F, McCarthy G, et al. Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J Hypertens 1991; 9:355-360.
31. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
32. Morgan T, Anderson A, Jones E, The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens 1997; 15:205-211.